Evidence map›Paper›PMID 34396108›Full record

ArticleBrain communications2021

Analysis of circulating protein aggregates as a route of investigation into neurodegenerative disorders.

Rocco Adiutori, Fabiola Puentes, Michael Bremang, Vittoria Lombardi, Irene Zubiri, Emanuela Leoni, Johan Aarum, Denise Sheer, Simon McArthur, Ian Pike and 1 more

Open access · goldAbstract read
In one paragraph

Article in Brain communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Rocco AdiutoriCentre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
Fabiola PuentesCentre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
Michael BremangProteome Sciences R&D GmbH & Co. KG, Frankfurt am Main 60438, Germany.
Vittoria LombardiCentre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
Irene ZubiriCentre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
Emanuela LeoniProteome Sciences R&D GmbH & Co. KG, Frankfurt am Main 60438, Germany.
Johan AarumDepartment of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden.
Denise SheerCentre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
Simon McArthurInstitute of Dentistry, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.ORCID https://orcid.org/0000-0001-8521-1808
Ian PikeProteome Sciences plc, Hamilton House, Mabledon Place, London WC1H 9BB, UK.
Andrea MalaspinaCentre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
Queen Mary University of London · GBKarolinska University Hospital · SEProteome Sciences (United Kingdom) · GB

Funding

Motor Neurone Disease Association MALASPINA/APR13/817-791Motor Neurone Disease Association TURNER/OCT15/972-797
6 · The paper itself

Abstract

Plasma proteome composition reflects the inflammatory and metabolic state of the organism and can be predictive of system-level and organ-specific pathologies. Circulating protein aggregates are enriched with neurofilament heavy chain-axonal proteins involved in brain aggregate formation and recently identified as biomarkers of the fatal neuromuscular disorder amyotrophic lateral sclerosis. Using unbiased proteomic methods, we have fully characterized the content in neuronal proteins of circulating protein aggregates from amyotrophic lateral sclerosis patients and healthy controls, with reference to brain protein aggregate composition. We also investigated circulating protein aggregate protein aggregation propensity, stability to proteolytic digestion and toxicity for neuronal and endothelial cell lines. Circulating protein aggregates separated by ultracentrifugation are visible as electron-dense macromolecular particles appearing as either large globular or as small filamentous formations. Analysis by mass spectrometry revealed that circulating protein aggregates obtained from patients are enriched with proteins involved in the proteasome system, possibly reflecting the underlying basis of dysregulated proteostasis seen in the disease, while those from healthy controls show enrichment of proteins involved in metabolism. Compared to the whole human proteome, proteins within circulating protein aggregates and brain aggregates show distinct chemical features of aggregation propensity, which appear dependent on the tissue or fluid of origin and not on the health status. Neurofilaments' two high-mass isoforms (460 and 268 kDa) showed a strong differential expression in amyotrophic lateral sclerosis compared to healthy control circulating protein aggregates, while aggregated neurofilament heavy chain was also partially resistant to enterokinase proteolysis in patients, demonstrated by immunoreactive bands at 171 and 31 kDa fragments not seen in digested healthy controls samples. Unbiased proteomics revealed that a total of 4973 proteins were commonly detected in circulating protein aggregates and brain, including 24 expressed from genes associated with amyotrophic lateral sclerosis. Interestingly, 285 circulating protein aggregate proteins (5.7%) were regulated (

Indexed as

biomarkersneurodegenerationneurofilamentsprotein aggregatesproteomics

Identifiers

PMID34396108
PMCPMC8361415
OpenAlexW3182095794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.